• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内分泌治疗对老年甲状腺乳头状癌患者术后预后的影响。

Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.

作者信息

Xia Qing, Dong Shuai, Bian Ping-Da, Wang Jue, Li Cheng-Jiang

机构信息

Department of Thyroid, The First Affiliated Hospital, College of Medicine, ZheJiang University, No 79, Qingchun Road, Hangzhou, 310003, China.

Department of Geriatrics, Zhejiang Province People's Hospital, Hangzhou, 310000, China.

出版信息

Eur Arch Otorhinolaryngol. 2016 Apr;273(4):1037-43. doi: 10.1007/s00405-015-3564-2. Epub 2015 Mar 6.

DOI:10.1007/s00405-015-3564-2
PMID:25744048
Abstract

Papillary thyroid carcinoma (PTC) is a common thyroid malignancy. Elderly patients have more severe disease and more complications following postoperative endocrine therapy to control thyroid-stimulating hormone (TSH) levels. We aimed to identify optimal postoperative serum TSH levels in elderly patients to prevent recurrence and metastasis and minimize complications. This retrospective cohort study collected data of 87 consecutive elderly patients (age >75) who underwent surgery for PTC with postoperative levothyroxine therapy (50-150 μg/d) between January 2006 and June 2008 and were followed until 2013. After 24 patients with TSH fluctuations and incomplete data were excluded, 73 patients were grouped based on postoperative TSH levels: Group A, 0.3-0.5 mIU/mL; Group B, 0.1-0.3 mIU/mL; and Group C <0.1 mIU/mL (n = 24, 25, 24, respectively). Subjects' baseline, preoperative data, postoperative complications and 1-, 3- and 5-year follow-up data were compared between groups. No significant differences in gender, age (median age of 80 years old), surgery type or clinical characteristics were found between groups (all p value >0.05). Postoperatively, all subjects had normal ECG and neck ultrasound, no osteoporosis, and no differences in survival rate or metastasis. Five-year follow-up revealed significant differences in development of arrhythmias, osteoporosis, insomnia and anxiety between Groups B (0.1-0.3 mIU/mL) and C (<0.1 mIU/mL) compared to Group A (0.3-0.5 mIU/mL). Postoperative incidence of PTC recurrence and metastasis remained stable in elderly patients undergoing thyroid surgery and endocrine therapy but complications increased significantly with increasing TSH levels. Controlling TSH to lower limits of normal may help prevent PTC recurrence and metastasis and reduce complications in this high-risk population.

摘要

乳头状甲状腺癌(PTC)是一种常见的甲状腺恶性肿瘤。老年患者在术后内分泌治疗以控制促甲状腺激素(TSH)水平后,病情更严重,并发症更多。我们旨在确定老年患者术后最佳血清TSH水平,以预防复发和转移,并将并发症降至最低。这项回顾性队列研究收集了2006年1月至2008年6月期间连续87例接受PTC手术并术后接受左甲状腺素治疗(50 - 150μg/d)的老年患者(年龄>75岁)的数据,并随访至2013年。排除24例TSH波动和数据不完整的患者后,73例患者根据术后TSH水平分组:A组,0.3 - 0.5 mIU/mL;B组,0.1 - 0.3 mIU/mL;C组<0.1 mIU/mL(分别为n = 24、25、24)。比较各组受试者的基线、术前数据、术后并发症以及1年、3年和5年的随访数据。各组之间在性别、年龄(中位年龄80岁)、手术类型或临床特征方面未发现显著差异(所有p值>0.05)。术后,所有受试者心电图和颈部超声均正常,无骨质疏松,生存率或转移方面无差异。五年随访显示,与A组(0.3 - 0.5 mIU/mL)相比,B组(0.1 - 0.3 mIU/mL)和C组(<0.1 mIU/mL)在心律失常、骨质疏松、失眠和焦虑的发生方面存在显著差异。接受甲状腺手术和内分泌治疗的老年患者术后PTC复发和转移的发生率保持稳定,但随着TSH水平升高,并发症显著增加。将TSH控制在正常下限可能有助于预防PTC复发和转移,并减少该高危人群的并发症。

相似文献

1
Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.内分泌治疗对老年甲状腺乳头状癌患者术后预后的影响。
Eur Arch Otorhinolaryngol. 2016 Apr;273(4):1037-43. doi: 10.1007/s00405-015-3564-2. Epub 2015 Mar 6.
2
Prediction of thyroid hormone supplementation after thyroid lobectomy.甲状腺叶切除术后甲状腺激素补充的预测。
J Surg Res. 2015 Jan;193(1):273-8. doi: 10.1016/j.jss.2014.07.003. Epub 2014 Jul 5.
3
Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.甲状腺叶切除术后停用左甲状腺素治疗甲状腺乳头状癌的成功率与良性肿瘤相当,与促甲状腺激素抑制的持续时间无关。
Anticancer Res. 2021 Nov;41(11):5713-5721. doi: 10.21873/anticanres.15387.
4
Preoperative subclinical hypothyroidism in patients with papillary thyroid carcinoma.甲状腺乳头状癌患者的术前亚临床甲状腺功能减退症。
Am J Otolaryngol. 2013 Jul-Aug;34(4):312-9. doi: 10.1016/j.amjoto.2012.12.013. Epub 2013 Jan 26.
5
Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.接受左甲状腺素单一疗法的甲状腺切除患者中反映甲状腺功能的生化标志物
Thyroid. 2017 Apr;27(4):484-490. doi: 10.1089/thy.2016.0426. Epub 2017 Feb 6.
6
Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.影响甲状腺乳头状癌术后患者促甲状腺激素抑制疗效的因素:一项回顾性队列研究
BMC Surg. 2024 May 3;24(1):133. doi: 10.1186/s12893-024-02426-y.
7
The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.低危型甲状腺乳头状癌患者行腺叶切除术 3 年后甲状腺功能的恢复情况:一项 3 年随访研究。
Front Endocrinol (Lausanne). 2021 Feb 9;11:619841. doi: 10.3389/fendo.2020.619841. eCollection 2020.
8
The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma.低危和中危乳头状甲状腺癌患者肺叶切除术后血清促甲状腺激素水平的预后价值
J Surg Oncol. 2018 Sep;118(3):390-396. doi: 10.1002/jso.25164. Epub 2018 Aug 16.
9
Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis.桥本甲状腺炎可能是甲状腺乳头状癌的一个危险因素,这可能会改善癌症的预后。
Otolaryngol Head Neck Surg. 2013 Mar;148(3):396-402. doi: 10.1177/0194599812472426. Epub 2013 Jan 8.
10
Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma.甲状腺乳头状癌患者甲状腺半切术后甲状腺功能减退及补充左甲状腺素的肿瘤学影响。
Head Neck. 2020 May;42(5):1004-1013. doi: 10.1002/hed.26075. Epub 2020 Jan 13.

引用本文的文献

1
Rising Incidence and Comorbidities of Endogenous Hypothyroidism in Republic of Korea from 2004 to 2018: A Nationwide Population Study.2004年至2018年韩国内源性甲状腺功能减退症的发病率上升及合并症情况:一项全国性人群研究
Endocrinol Metab (Seoul). 2024 Dec;39(6):891-898. doi: 10.3803/EnM.2024.1996. Epub 2024 Sep 23.
2
Therapeutic Approaches to Increase the Survival Rate of Cancer Patients in the Younger and Older Population.提高年轻和老年癌症患者生存率的治疗方法。
Curr Aging Sci. 2024;17(1):16-30. doi: 10.2174/0118746098241507231127114248.
3
Differentiated thyroid carcinoma in the elderly: influence of age on disease-free and overall survival.

本文引用的文献

1
Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis.韩国桥本甲状腺炎患者甲状腺乳头状癌风险升高。
Head Neck. 2011 May;33(5):691-5. doi: 10.1002/hed.21518. Epub 2010 Nov 10.
2
Differentiated thyroid cancer.分化型甲状腺癌。
Semin Oncol. 2010 Dec;37(6):557-66. doi: 10.1053/j.seminoncol.2010.10.008.
3
A novel HSP90 modulator with selective activity against thyroid cancers in vitro.一种在体外对甲状腺癌具有选择性活性的新型热休克蛋白90(HSP90)调节剂。
老年甲状腺分化癌:年龄对无病生存和总体生存的影响。
Endocrine. 2022 Jun;77(1):121-133. doi: 10.1007/s12020-022-03059-y. Epub 2022 May 18.
4
CREB3 Transactivates lncRNA ZFAS1 to Promote Papillary Thyroid Carcinoma Metastasis by Modulating miR-373-3/MMP3 Regulatory Axis.CREB3通过调节miR-373-3/MMP3调控轴反式激活长链非编码RNA ZFAS1以促进甲状腺乳头状癌转移。
Int J Endocrinol. 2021 Jun 21;2021:9981683. doi: 10.1155/2021/9981683. eCollection 2021.
5
MicroRNA-363-3p downregulation in papillary thyroid cancer inhibits tumor progression by targeting NOB1.微小 RNA-363-3p 在甲状腺乳头状癌中的下调通过靶向 NOB1 抑制肿瘤进展。
J Investig Med. 2021 Jan;69(1):66-74. doi: 10.1136/jim-2020-001562. Epub 2020 Oct 19.
6
MiR-145 functions as a tumor suppressor in Papillary Thyroid Cancer by inhibiting RAB5C.miR-145 通过抑制 RAB5C 在甲状腺乳头状癌中发挥肿瘤抑制作用。
Int J Med Sci. 2020 Jul 25;17(13):1992-2001. doi: 10.7150/ijms.44723. eCollection 2020.
7
Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism.甲状腺激素的致心律失常信号及其在亚临床甲状腺功能亢进症中的相关性。
Int J Mol Sci. 2020 Apr 19;21(8):2844. doi: 10.3390/ijms21082844.
8
Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.用于改善甲状腺癌患者预后的多组学特征及转化潜力
Cancers (Basel). 2019 Dec 10;11(12):1988. doi: 10.3390/cancers11121988.
9
Thyroid hormone therapy in differentiated thyroid cancer.分化型甲状腺癌的甲状腺激素治疗。
Endocrine. 2019 Oct;66(1):43-50. doi: 10.1007/s12020-019-02051-3. Epub 2019 Oct 15.
10
Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma.Let-7a通过靶向甲状腺乳头状癌中的AKT2来抑制迁移、侵袭和肿瘤生长。
Oncotarget. 2017 Jul 15;8(41):69746-69755. doi: 10.18632/oncotarget.19261. eCollection 2017 Sep 19.
Surgery. 2009 Dec;146(6):1196-207. doi: 10.1016/j.surg.2009.09.028.
4
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.美国甲状腺协会修订的甲状腺结节和分化型甲状腺癌患者管理指南。
Thyroid. 2009 Nov;19(11):1167-214. doi: 10.1089/thy.2009.0110.
5
Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.分化型甲状腺癌:ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:143-6. doi: 10.1093/annonc/mdp156.
6
Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma.甲状腺乳头状癌的诊断、治疗、预后因素及长期结局
Minerva Endocrinol. 2008 Dec;33(4):359-79.
7
Risk-stratified management of well-differentiated thyroid cancers: a review of experience from a single institution, 1990-2003.高分化甲状腺癌的风险分层管理:来自单一机构1990 - 2003年经验的综述
World J Surg. 2008 Mar;32(3):386-94. doi: 10.1007/s00268-007-9343-5.
8
Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.术前未检测到侧方淋巴结转移的甲状腺乳头状癌患者淋巴结复发的危险因素:预防性改良根治性颈清扫术的有效性
World J Surg. 2007 Nov;31(11):2085-91. doi: 10.1007/s00268-007-9224-y.
9
Outcomes of patients with differentiated thyroid carcinoma following initial therapy.分化型甲状腺癌患者初始治疗后的结局。
Thyroid. 2006 Dec;16(12):1229-42. doi: 10.1089/thy.2006.16.1229.
10
Thyroid-hormone therapy and thyroid cancer: a reassessment.甲状腺激素疗法与甲状腺癌:重新评估
Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):32-40. doi: 10.1038/ncpendmet0020.